top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)

AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.

Click here now for the full details of this stock that’s set to rocket in the AI revolution…

Michael Castagna net worth and biography

Michael Castagna Biography and Net Worth

CEO of MannKind

Michael Castagna is the CEO of MannKind Corporation, a role he has held since March 2016. He also serves on the company’s board of directors.

MannKind is a biopharmaceutical company focused on discovery, development, and commercialization of therapeutics for diseases like diabetes and pulmonary arterial hypertension. In his role as CEO, Dr. Castagna is focused on strategic development of the company’s people and products.

Dr. Castagna had a 14-year career as a pharmacist with CVS before fully transitioning to the business side of the industry. Before joining MannKind, he held various executive positions at Merck Serono, Sandoz, Pharmasett, Bristol-Myers Squibb, and most recently, Amgen, where he served as vice president, global commercial lead for a portfolio of nine biosimilar drugs.

While at BMS, he helped lead the relaunch of Orencia IV and the launch of Orencia SC, both drugs targeting rheumatoid arthritis. At Sandoz, he helped relaunch its lead product, a human growth hormone called Omnitrope.

In his free time, Castagna serves on the board of directors of Pet Partners, a nonprofit organization with a mission of improving people’s health through positive interactions with therapy animals.

He earned his B.S. in pharmacy from the University of the Sciences in Philadelphia, his M.B.A. in entrepreneurial studies from the University of Pennsylvania’s Wharton School of Business, and his doctor of pharmacy degree from the Massachusetts College of Pharmacy and Health Sciences.

What is Michael Castagna's net worth?: The estimated net worth of Michael Castagna is at least $9.20 million as of December 14th, 2023. Dr. Castagna owns 2,239,147 shares of MannKind stock worth more than $9,202,894 as of April 23rd. This net worth evaluation does not reflect any other investments that Dr. Castagna may own. Additionally, Dr. Castagna receives a salary of $1,260,000.00 as CEO at MannKind. Learn More about Michael Castagna's net worth.
How old is Michael Castagna?: Dr. Castagna is currently 47 years old. There are 9 older executives and no younger executives at MannKind. Learn More on Michael Castagna's age.
What is Michael Castagna's salary?: As the CEO of MannKind Co., Dr. Castagna earns $1,260,000.00 per year. Learn More on Michael Castagna's salary.
How do I contact Michael Castagna?: The corporate mailing address for Dr. Castagna and other MannKind executives is 30930 RUSSELL RANCH ROAD SUITE 300, WESTLAKE VILLAGE CA, 91362. MannKind can also be reached via phone at (818) 661-5000 and via email at [email protected]. Learn More on Michael Castagna's contact information.
Has Michael Castagna been buying or selling shares of MannKind?: Michael Castagna has not been actively trading shares of MannKind during the past quarter. Most recently, Michael Castagna sold 110,000 shares of the business's stock in a transaction on Thursday, December 14th. The shares were sold at an average price of $4.00, for a transaction totalling $440,000.00. Following the completion of the sale, the chief executive officer now directly owns 2,239,147 shares of the company's stock, valued at $8,956,588. Learn More on Michael Castagna's trading history.
Who are MannKind's active insiders?: MannKind's insider roster includes Steven Binder (CFO), Michael Castagna (CEO), Alejandro Galindo (Insider), David Thomson (EVP), and Stuart Tross (Insider). Learn More on MannKind's active insiders.
Are insiders buying or selling shares of MannKind?: In the last twelve months, insiders at the biopharmaceutical company sold shares 13 times. They sold a total of 556,486 shares worth more than $2,496,686.38. The most recent insider tranaction occured on December, 14th when CEO Michael Castagna sold 110,000 shares worth more than $440,000.00. Insiders at MannKind own 3.0% of the company. Learn More about insider trades at MannKind.
Information on this page was last updated on 12/14/2023.

Michael Castagna Insider Trading History at MannKind

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/14/2023	Sell	110,000	$4.00	$440,000.00	2,239,147
11/1/2023	Sell	10,000	$4.25	$42,500.00	2,349,147
10/2/2023	Sell	10,000	$4.61	$46,100.00	2,359,147
9/1/2023	Sell	10,000	$4.61	$46,100.00	2,436,039
8/1/2023	Sell	10,000	$4.57	$45,700.00	2,496,735
7/3/2023	Sell	10,000	$4.07	$40,700.00	2,506,735
6/1/2023	Sell	10,000	$4.53	$45,300.00	2,516,735
5/26/2023	Sell	75,000	$4.50	$337,500.00	2,526,735
5/24/2023	Sell	150,000	$4.69	$703,500.00	2,331,735
5/5/2023	Sell	10,000	$4.00	$40,000.00	2,020,128
4/3/2023	Sell	10,000	$4.13	$41,300.00	2,030,128
3/1/2023	Sell	10,000	$5.27	$52,700.00	2,040,128
7/31/2022	Buy	3,147	$2.93	$9,220.71	2,084,486
7/30/2021	Buy	5,000	$2.99	$14,950.00
3/5/2021	Buy	3,000	$3.38	$10,140.00
6/15/2020	Buy	30,000	$1.49	$44,700.00	198,560
6/12/2020	Buy	68	$1.41	$95.88	198,560
1/31/2019	Buy	5,000	$1.07	$5,350.00	98,157
8/2/2018	Buy	5,000	$1.31	$6,550.00	68,157
12/20/2017	Buy	8,000	$2.29	$18,320.00	35,532
8/26/2016	Buy	17,500	$0.78	$13,650.00	212,500
8/24/2016	Buy	15,000	$0.87	$13,050.00	195,000
8/23/2016	Buy	25,000	$0.94	$23,500.00	180,000
8/12/2016	Buy	25,000	$1.00	$25,000.00	75,000
5/17/2016	Buy	50,000	$0.93	$46,500.00	50,000

Michael Castagna Buying and Selling Activity at MannKind

MannKind Company Overview

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

Today's Range

Now: $4.16

$4.06

$4.25

50 Day Range

MA: $4.30

$3.40

$5.27

2 Week Range

Now: $4.16

$3.17

$5.75

Volume

1,020,671 shs

Average Volume

2,977,856 shs

Market Capitalization

$1.13 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.28

top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)

From Traders Agency | Ad

Click here now for the full details of this stock that’s set to rocket in the AI revolution…

Michael Castagna Biography and Net Worth

What is Michael Castagna's net worth?

How old is Michael Castagna?

What is Michael Castagna's salary?

How do I contact Michael Castagna?

Has Michael Castagna been buying or selling shares of MannKind?

Who are MannKind's active insiders?

Are insiders buying or selling shares of MannKind?